59 related articles for article (PubMed ID: 12802933)
1. Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS).
Rao VK; Price S; Perkins K; Aldridge P; Tretler J; Davis J; Dale JK; Gill F; Hartman KR; Stork LC; Gnarra DJ; Krishnamurti L; Newburger PE; Puck J; Fleisher T
Pediatr Blood Cancer; 2009 Jul; 52(7):847-52. PubMed ID: 19214977
[TBL] [Abstract][Full Text] [Related]
2. Immune- and Non-Immune-Mediated Adverse Effects of Monoclonal Antibody Therapy: A Survey of 110 Approved Antibodies.
Baldo BA
Antibodies (Basel); 2022 Feb; 11(1):. PubMed ID: 35323191
[TBL] [Abstract][Full Text] [Related]
3. An Uncharacteristic Presentation of Evans Syndrome Following Treatment With Dupilumab.
Rutherford M; Tran M; Salazar L; Iqbal F; Mazharuddin A; Camarena J
Cureus; 2021 Jul; 13(7):e16658. PubMed ID: 34462689
[TBL] [Abstract][Full Text] [Related]
4. Anti-erythropoietin receptor antibody-associated pure red cell aplasia accompanied by Coombs-negative autoimmune hemolytic anemia in a patient with T cell/histiocyte-rich large B cell lymphoma.
Fujimi A; Kamihara Y; Kanisawa Y; Hashimoto A; Nakajima C; Hayasaka N; Uemura N; Okuda T; Minami S; Iyama S; Takada K; Sato T; Hara A; Iwata Y; Furuichi K; Wada T; Kato J
Int J Hematol; 2014 Nov; 100(5):490-3. PubMed ID: 25096221
[TBL] [Abstract][Full Text] [Related]
5. Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses.
Baldo BA
Oncoimmunology; 2013 Oct; 2(10):e26333. PubMed ID: 24251081
[TBL] [Abstract][Full Text] [Related]
6. Rituximab therapy in a patient with autoimmune hemolytic anemia and immune thrombocytopenia associated with chronic lymphocytic leukemia.
Aleem A
Ann Saudi Med; 2008; 28(5):382-5. PubMed ID: 18779631
[No Abstract] [Full Text] [Related]
7. Diagnosis and treatment of autoimmune haemolytic anaemias in adults: a clinical review.
Valent P; Lechner K
Wien Klin Wochenschr; 2008; 120(5-6):136-51. PubMed ID: 18365153
[TBL] [Abstract][Full Text] [Related]
8. Ofatumumab in rituximab-refractory autoimmune hemolytic anemia associated with chronic lymphocytic leukemia: a case report and review of literature.
Nader K; Patel M; Ferber A
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):511-3. PubMed ID: 23726016
[No Abstract] [Full Text] [Related]
9. Severe autoimmune hemolytic anemia following rituximab therapy in a patient with a lymphoproliferative disorder.
Jourdan E; Topart D; Richard B; Jourdan J; Sotto A
Leuk Lymphoma; 2003 May; 44(5):889-90. PubMed ID: 12802933
[TBL] [Abstract][Full Text] [Related]
10. Rituximab in B-cell disorders other than non-Hodgkin's lymphoma.
Bosly A; Keating MJ; Stasi R; Bradstock K
Anticancer Drugs; 2002 Nov; 13 Suppl 2():S25-33. PubMed ID: 12710588
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases.
Zaja F; Vianelli N; Sperotto A; Patriarca F; Tani M; Marin L; Tiribelli M; Candoni A; Baccarani M; Fanin R
Leuk Lymphoma; 2003 Nov; 44(11):1951-5. PubMed ID: 14738149
[TBL] [Abstract][Full Text] [Related]
12. Beneficial effects of rituximab on primary cold agglutinin disease refractory to conventional therapy.
Mori A; Tamaru J; Sumi H; Kondo H
Eur J Haematol; 2002 Apr; 68(4):243-6. PubMed ID: 12071942
[TBL] [Abstract][Full Text] [Related]
13. Fludarabine-induced hemolytic anemia: successful treatment by rituximab.
Paydas S
Hematol J; 2004; 5(1):81-3. PubMed ID: 14745435
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
